The Orphan Drug Designation Program offers orphan status to biologics and drugs that are safe and effective for rare diseases; also for prevention use.
The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.
A 3-part strategy was announced to combat the hepatitis A outbreak in San Diego, California.
Experts discuss screening, treatment, and other considerations in pediatric HCV.
Researchers compared the safety and efficacy of sofosbuvir plus ledipasvir vs pegylated interferon and ribavirin for 12 weeks in patients with thalassemia major and hepatitis C virus genotype 1 or 4.
HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.
More interventions are needed to meet the target of hepatitis C virus elimination in the country of Georgia, defined as a 90% reduction in prevalence by 2020.
The first dose of the hepatitis B vaccine should be given within the first 24 hours of life.
Non-specialists, including primary care providers and nurse practitioners, safely and effectively administer direct-acting antiviral therapy for hepatitis C virus to patients seen in FQHCs.
One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access to suitable treatment.
The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.
The World Health Organization published a position paper with updated recommendations on the use of the hepatitis B vaccine regarding target groups, immunization schedules, and storage and distribution.
Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and mortality.
Steatosis, hypertension, older age, obesity, and HIV are risk factors for liver fibrosis in African-Americans with chronic hepatitis C.
Using an electronic health record-based can improve HCV screening rates among baby boomers.
FDA has approved Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C virus.
Patients with HCV are at risk for several extrahepatic sequelae. Find out what they are and the new treatment options for managing HCV in patients with rheumatic symptoms.
Fixed-dose ledipasvir-sofosbuvir plus weight-based ribavirin may offer a treatment alternative in treatment-naïve patients with non-cirrhotic GT3 HCV.
For patients with chronic hepatitis B, achievement of subcirrhotic range of liver stiffness with antiviral therapy is linked to lower risk of hepatocellular carcinoma.
A noninvasive oral fluid-based immunoassay has high sensitivity and specificity for identifying recent and past hepatitis E virus.
The FDA approved Vosevi for the retreatment of adults with chronic hepatitis C virus genotypes 1-6.
A study showed that telbivudine administered during early and middle pregnancy prevented transmission of hepatitis B virus infection from mother to infants in all participants receiving antiviral treatment.
Direct-acting antiviral treatment of hepatitis C virus improved glycemic control for patients with type 2 diabetes.
Hepatocellular carcinoma decreases beyond year 5 of entecavir/tenofovir therapy in Caucasian patients with chronic hepatitis B virus.
Point-of-care test was found to have high sensitivity and specificity for detecting HCV RNA in both capillary whole-blood samples collected by finger stick and in plasma samples collected by venipuncture.
Expert insight from Leslie B. Lilly, MD, FRCPC, medical director of GI Transplantation from the Toronto General Hospital in Canada, about direct-acting antivirals in the management of hepatitis C virus in the liver transplantation setting.
The European Association for the Study of the Liver raises concerns over Cochrane Review of direct acting antivirals for hepatitis C virus.
For patients with HCV and HIV coinfection, treatment is effective with standardized nurse/pharmacist support at urban clinics.
The Turkish Society of Rheumatology proposed a guideline of hepatitis screening in patients with rheumatoid arthritis.
Liver cancer has become the fastest growing cause of cancer deaths in the Unites States.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- HCC Risk After HCV Direct-Acting Antiviral Treatment
- Influenza Vaccine's Effectiveness Following Repeated Vaccination
- FDA Announces Orphan Drug Designation for HDV Drug
- New Single-Assay Test for Vaginitis Accurate as Traditional Tests
- Dexamethasone Reduces Need for Antibiotics in Adults With Sore Throat
- Bezlotoxumab Reduces 30-Day Hospital Readmissions for C difficile Infection
- FDA: Vabomere Approved for Complicated UTI Following Priority Review
- HCC Risk After HCV Direct-Acting Antiviral Treatment
- New CDC Guidelines for SSI Prevention Leave Unanswered Questions
- Clinic Visits, Costs Decreased by Rotavirus Vaccination in US Children
- Risk for Secondary Tumors After Kaposi Sarcoma Has Changed in the HAART Era
- FDA Approval: Single-Dose Oral Therapy for Bacterial Vaginosis
- HIV Risk Behaviors More Prominent in Women With Mental Disorders
- Influenza Vaccine in Elderly Adults: Is High-Dose Better Than Standard-Dose?
- Once-Daily Single-Tablet HIV Treatment Safe, Effective in Children